Wei Guo Su

Chief Executive Officer presso HUTCHMED (CHINA) LIMITED

Patrimonio netto: 16 M $ in data 31/03/2024

66 anni

Health Technology

Consumer Services

Posizioni attive di Wei Guo Su

Società	Posizione	Inizio	Fine
HUTCHMED (CHINA) LIMITED	Director/Board Member	27/03/2017	-
	Chief Executive Officer	04/03/2022	-
	Chief Tech/Sci/R&D Officer	01/01/2012	-
Hutchison MediPharma Ltd. Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China.	Chief Tech/Sci/R&D Officer	24/03/2010	-

Società	Posizione	Inizio	Fine
PFIZER, INC.	Corporate Officer/Principal	-	-

Harvard University	Doctorate Degree
Fudan University	Undergraduate Degree

Distribuzione geografica

Posizioni

Chief Tech/Sci/R&D Officer	2
Corporate Officer/Principal	1
Doctorate Degree	1

Settori

Health Technology	4
Consumer Services	3

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	2
PFIZER, INC.	Health Technology
HUTCHMED (CHINA) LIMITED	Health Technology

Aziende private	1
Hutchison MediPharma Ltd. Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China.	Health Technology